AI assistant
UroGen Pharma Ltd. — Director's Dealing 2024
Feb 12, 2024
32312_dirs_2024-02-12_3aa10a05-ab73-4a03-9859-8d4413eb3f88.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2022-03-25
Reporting Person: Kim Dong (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-03-25 | Stock Option (right to buy) | $8.61 | A | 20000 | Acquired | 2032-03-25 | Ordinary Shares (20000) | Direct |
Footnotes
F1: One third of the shares underlying the stock option will vest on each of March 25, 2023, March 25, 2024 and March 25, 2025.
F2: This amendment corrects and restates the number of derivative securities acquired reported in the original Form 4 filed on March 29, 2022.
F3: This amendment corrects and restates the expiration date reported in the original Form 4 filed on March 29, 2022.
F4: This amendment corrects and restates the amount of securities underlying derivative security reported in the original Form 4 filed on March 29, 2022.
F5: This amendment corrects and restates the number of derivative securities beneficially owned following reported transaction reported in the original Form 4 filed on March 29, 2022.